MedPath

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Phase 3
Completed
Conditions
Stage IV or Recurrent Non-Small Cell Lung Cancer
Interventions
Registration Number
NCT02041533
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
541
Inclusion Criteria
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1
  • Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapy
  • Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria
  • PD-L1+ on immunohistochemistry testing performed by central lab
  • Men and women, ages ≥ 18 years of age
Read More
Exclusion Criteria
  • Known epidermal growth factor receptor (EGFR) mutations which are sensitive to available targeted inhibitor therapy
  • Known anaplastic lymphoma kinase (ALK) translocations
  • Untreated central nervous system (CNS) metastases
  • Previous malignancies
  • Active, known or suspected autoimmune disease
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm A: Nivolumab subjectsNivolumabNivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
Arm B: Investigator's Choice ChemotherapyNivolumabInvestigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first Squamous subjects: * Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or * Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or * Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle Non-Squamous subjects: * Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle * Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle Optional crossover: * Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure
Arm B: Investigator's Choice ChemotherapyGemcitabineInvestigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first Squamous subjects: * Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or * Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or * Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle Non-Squamous subjects: * Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle * Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle Optional crossover: * Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure
Arm B: Investigator's Choice ChemotherapyCarboplatinInvestigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first Squamous subjects: * Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or * Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or * Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle Non-Squamous subjects: * Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle * Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle Optional crossover: * Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure
Arm B: Investigator's Choice ChemotherapyCisplatinInvestigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first Squamous subjects: * Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or * Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or * Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle Non-Squamous subjects: * Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle * Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle Optional crossover: * Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure
Arm B: Investigator's Choice ChemotherapyPemetrexedInvestigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first Squamous subjects: * Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or * Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or * Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle Non-Squamous subjects: * Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle * Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle Optional crossover: * Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure
Arm B: Investigator's Choice ChemotherapyPaclitaxelInvestigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first Squamous subjects: * Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or * Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or * Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle Non-Squamous subjects: * Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle * Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle Optional crossover: * Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival in Participants With PD-L1 Expression >= 5%From date of randomization until date of documented tumor progression (assessed up to August 2016, approximately 28 months)

Progression-Free Survival (PFS) was defined as the time between the date of randomization and the first date of documented tumor progression, as determined by the Independent Radiology Review Committee (IRRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever occurs first. Participants who die without a reported progression were considered to have progressed on the date of their death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the day they were randomized. Participants who received subsequent anti-cancer therapy prior to documented progression were censored at the last evaluable tumor assessment prior to the initiation of new therapy.

Secondary Outcome Measures
NameTimeMethod
Progression-Free Survival in All Randomized ParticipantsFrom date of randomization until date of documented tumor progression (assessed up to August 2016, approximately 28 months)

Progression-Free Survival (PFS) was defined as the time between the date of randomization and the first date of documented tumor progression, as determined by the Independent Radiology Review Committee (IRRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever occurs first. Participants who die without a reported progression were considered to have progressed on the date of their death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who did not have any on-study tumor assessments and did not die were censored on the day they were randomized. Participants who received subsequent anti-cancer therapy prior to documented progression were censored at the last evaluable tumor assessment prior to the initiation of new therapy.

Overall Survival in Participants With PD-L1 Expression >= 5%From date of randomization to date of death (up to approximately 89 months)

Overall Survival (OS) was defined as the time from randomization to the date of death. A participant who had not died was censored at the last known alive date. OS was censored at the date of randomization for participants who were randomized but had no follow-up.

Overall Survival in All Randomized ParticipantsFrom date of randomization to date of death (up to approximately 89 months)

Overall Survival (OS) was defined as the time from randomization to the date of death. A participant who had not died was censored at the last known alive date. OS was censored at the date of randomization for participants who were randomized but had no follow-up.

Objective Response Rate (ORR) in Participants With PD-L1 Expression >= 5%From date of randomization until date of documented tumor progression or subsequent anti-cancer therapy, whichever occurs first (assessed up to August 2016, approximately 28 months)

ORR was defined as the proportion of randomized participants who achieved a Best Overall Response (BOR) of CR or PR using the RECIST v1.1 criteria per Independent Radiology Review Committee (IRRC) assessment. BOR was defined as the best response designation recorded between the date of randomization and the date of objectively documented progression or start of subsequent anti-cancer therapy, whichever occurred first. For participants without documented progression or subsequent therapy, all available response designations contributed to the BOR assessment. For participants who continued treatment beyond progression, BOR was determined from response designations recorded up to the time of initial progression. CR= Disappearance of all evidence of disease, confirmed by PET scan; PR= Regression of measureable disease and no new sites; Stable Disease (SD)= Failure to attain CR/PR or PD; Progressive Disease (PD)= Any new lesion or increase by \>=50% of previously involved sites from nadir.

Disease-related Symptom Improvement Rate by Week 12From date of randomization to week 12

The Lung Cancer Symptom Score (LCSS) is a validated instrument designed to assess the impact of treatment on disease-related symptoms. It consists of 6 symptom-specific questions related to dyspnea, cough, fatigue, pain, hemoptysis and anorexia plus 3 summary items: symptom distress, interference with activity, and global HRQoL. The degree of impairment was recorded on a 100 mm visual analogue scale with scores from 0 to 100 with zero representing the best score. Disease-related symptom improvement rate by Week 12 is defined as the proportion of all randomized (all PD-L1+) participants who had 10 points or more decrease from baseline in average symptom burden index score at any time between randomization and Week 12.

Trial Locations

Locations (141)

Local Institution - 0159

🇯🇵

Akashi, Hyogo, Japan

Southern Cancer Center, Inc.

🇺🇸

Mobile, Alabama, United States

Banner MD Anderson Cancer Center

🇺🇸

Gilbert, Arizona, United States

Local Institution - 0037

🇺🇸

Chicago, Illinois, United States

Local Institution - 0027

🇺🇸

Columbus, Ohio, United States

Local Institution - 0054

🇺🇸

Philadelphia, Pennsylvania, United States

Local Institution - 0002

🇺🇸

Philadelphia, Pennsylvania, United States

Local Institution - 0018

🇺🇸

Pittsburgh, Pennsylvania, United States

Local Institution - 0006

🇺🇸

Dallas, Texas, United States

Local Institution - 0072

🇦🇺

Fitzroy, Victoria, Australia

Local Institution - 0113

🇨🇦

Toronto, Ontario, Canada

Local Institution - 0130

🇹🇷

Kayseri, Turkey

H. Lee Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

Local Institution - 0033

🇺🇸

Ocala, Florida, United States

Crescent City Research Consortium, LLC

🇺🇸

Marrero, Louisiana, United States

Local Institution - 0011

🇺🇸

Charleston, South Carolina, United States

Local Institution - 0038

🇺🇸

Greenville, South Carolina, United States

Local Institution - 0034

🇺🇸

Tucson, Arizona, United States

University Of Colorado Hosp

🇺🇸

Aurora, Colorado, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

Local Institution - 0062

🇧🇪

Leuven, Belgium

Local Institution - 0016

🇺🇸

Stanford, California, United States

Local Institution - 0010

🇺🇸

Atlanta, Georgia, United States

Local Institution - 0020

🇺🇸

New Haven, Connecticut, United States

Local Institution - 0104

🇦🇺

Heidelberg, Victoria, Australia

Local Institution - 0094

🇭🇺

Matrahaza, Hungary

Local Institution - 0063

🇩🇪

Koeln, Germany

Local Institution - 0052

🇦🇷

Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina

Local Institution - 0105

🇫🇷

Lille, France

Local Institution - 0044

🇧🇪

Brussels, Belgium

Local Institution - 0055

🇧🇪

Edegem, Belgium

Local Institution - 0058

🇨🇿

Praha 8, Czechia

Local Institution - 0049

🇦🇷

Capital Federal, Buenos Aires, Argentina

Local Institution - 0109

🇨🇦

Rimouski, Quebec, Canada

Local Institution - 0003

🇺🇸

Durham, North Carolina, United States

Oregon Health & Science University

🇺🇸

Portland, Oregon, United States

Local Institution - 0005

🇺🇸

New York, New York, United States

Local Institution - 0051

🇦🇷

Berazategui, Buenos Aires, Argentina

Local Institution - 0060

🇨🇿

Usti nad Labem, Czechia

Local Institution - 0056

🇧🇪

Gent, Belgium

Local Institution - 0059

🇨🇿

Olomouc, Czechia

Local Institution - 0064

🇩🇪

Heidelberg, Germany

Local Institution - 0048

🇦🇷

Cordoba, Argentina

Local Institution - 0135

🇧🇷

Barretos, Sao Paulo, Brazil

Local Institution - 0140

🇫🇷

Strasbourg, France

Local Institution - 0118

🇫🇮

Vaasa, Finland

Local Institution - 0102

🇫🇷

Marseille Cedex 20, France

Local Institution - 0061

🇨🇿

Ostrava - Poruba, Czechia

Local Institution - 0100

🇫🇷

Rennes Cedex 9, France

Local Institution - 0073

🇬🇷

Heraklion, Creta, Greece

Local Institution - 0110

🇨🇦

Montreal, Quebec, Canada

Local Institution - 0116

🇭🇺

Debrecen, Hungary

Local Institution - 0167

🇫🇷

Pontoise Cedex, France

Local Institution - 0066

🇩🇪

Stuttgart, Germany

Local Institution - 0123

🇫🇷

Caen, France

Local Institution - 0127

🇸🇪

Stockholm, Sweden

Local Institution - 0039

🇪🇸

Sevilla, Spain

Local Institution - 0097

🇬🇧

Manchester, Greater Manchester, United Kingdom

Local Institution - 0053

🇬🇧

Leeds, Yorkshire, United Kingdom

Local Institution - 0024

🇺🇸

Baltimore, Maryland, United States

Local Institution - 0030

🇺🇸

Miami, Florida, United States

Local Institution - 0036

🇺🇸

Boston, Massachusetts, United States

Local Institution - 0023

🇺🇸

Houston, Texas, United States

Local Institution - 0070

🇺🇸

Boston, Massachusetts, United States

Local Institution - 0075

🇬🇷

Athens, Greece

Local Institution - 0133

🇧🇷

Porto Alegre, Rio Grande Do Sul, Brazil

Local Institution - 0087

🇦🇹

Wien, Austria

Local Institution - 0120

🇫🇮

Helsinki, Finland

Local Institution - 0122

🇲🇽

Guadalajara, Jalisco, Mexico

Local Institution - 0069

🇷🇴

Ploiesti, Romania

Local Institution - 0077

🇨🇭

Lausanne, Switzerland

Local Institution - 0088

🇦🇹

Wels, Austria

Local Institution - 0154

🇯🇵

Chuo-ku, Tokyo, Japan

Local Institution - 0090

🇦🇺

Camperdown, New South Wales, Australia

Northwest Georgia Oncology Center, P.C.

🇺🇸

Marietta, Georgia, United States

Local Institution - 0007

🇺🇸

Allentown, Pennsylvania, United States

Local Institution - 0008

🇺🇸

Nashville, Tennessee, United States

Local Institution - 0029

🇺🇸

Yakima, Washington, United States

Local Institution - 0086

🇨🇦

Calgary, Alberta, Canada

Local Institution - 0163

🇰🇷

Seoul, Korea, Republic of

Local Institution - 0098

🇬🇧

London, Greater London, United Kingdom

Local Institution - 0014

🇺🇸

Lexington, Kentucky, United States

Local Institution - 0009

🇺🇸

New York, New York, United States

University Of North Carolina At Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

Local Institution - 0012

🇺🇸

Cleveland, Ohio, United States

Cancer Centers of South Texas

🇺🇸

San Antonio, Texas, United States

Local Institution - 0050

🇦🇷

Cordoba, Argentina

Local Institution - 0091

🇦🇺

Brisbane, Queensland, Australia

Local Institution - 0071

🇦🇺

Elizabeth Vale, South Australia, Australia

Local Institution - 0119

🇫🇮

Tampere, Finland

Local Institution - 0134

🇧🇷

Ijui, Rio Grande Do Sul, Brazil

Local Institution - 0115

🇨🇦

Hamilton, Ontario, Canada

Local Institution - 0074

🇩🇪

Bamberg, Germany

Local Institution - 0065

🇩🇪

Grosshansdorf, Germany

Local Institution - 0092

🇩🇪

Wiesbaden, Germany

Local Institution - 0126

🇭🇺

Budapest, Hungary

Local Institution - 0084

🇮🇹

Avellino, Italy

Local Institution - 0142

🇮🇹

Napoli, Italy

Local Institution - 0079

🇮🇹

Livorno, Italy

Local Institution - 0143

🇮🇹

Milano, Italy

Local Institution - 0153

🇯🇵

Kobe City, Hyogo, Japan

Local Institution - 0151

🇯🇵

Niigata-shi, Niigata, Japan

Local Institution - 0161

🇯🇵

Nagoya-shi, Aichi, Japan

Local Institution - 0146

🇯🇵

Nagoya, Aichi, Japan

Local Institution - 0082

🇮🇹

Terni, Italy

Local Institution - 0148

🇯🇵

Matsuyama-shi, Ehime, Japan

Local Institution - 0083

🇮🇹

Perugia, Italy

Local Institution - 0144

🇯🇵

Natori-shi, Miyagi, Japan

Local Institution - 0147

🇯🇵

Miyakojima-ku, Osaka, Japan

Local Institution - 0150

🇯🇵

Kitaadachi-gun, Saitama, Japan

Local Institution - 0166

🇯🇵

Habikino-shi, Osaka, Japan

Local Institution - 0145

🇯🇵

Osaka-sayama, Osaka, Japan

Local Institution - 0152

🇯🇵

Sakai, Osaka, Japan

Local Institution - 0149

🇯🇵

Sunto-gun, Shizuoka, Japan

Local Institution - 0165

🇯🇵

Sapporo, Hokkaido, Japan

Local Institution - 0162

🇯🇵

Ota, Gunma, Japan

Local Institution - 0160

🇯🇵

Tokyo, Japan

Local Institution - 0158

🇯🇵

Wakayama, Japan

Local Institution - 0155

🇰🇷

Gangnam-gu, Korea, Republic of

Local Institution - 0164

🇰🇷

Seoul, Korea, Republic of

Local Institution - 0117

🇲🇽

Mexico, Distrito Federal, Mexico

Local Institution - 0124

🇲🇽

Merida, Yucatan, Mexico

Local Institution - 0045

🇳🇱

Amsterdam, Netherlands

Local Institution - 0057

🇳🇱

Groningen, Netherlands

Local Institution - 0046

🇳🇱

Rotterdam, Netherlands

Local Institution - 0114

🇵🇱

Bydgoszcz, Poland

Local Institution - 0089

🇵🇱

Warszawa, Poland

Local Institution - 0139

🇵🇱

Lodz, Poland

Local Institution - 0131

🇵🇱

Krakow, Poland

Local Institution - 0093

🇵🇱

Wodzislaw Slaski, Poland

Local Institution - 0067

🇷🇴

Cluj-napoca, Romania

Local Institution - 0068

🇷🇴

Cluj Napoca, Romania

Local Institution - 0040

🇪🇸

Barcelona, Spain

Local Institution - 0042

🇪🇸

Malaga, Spain

Local Institution - 0041

🇪🇸

Las Palmas De Gran Canaria, Spain

Local Institution - 0043

🇪🇸

Valencia, Spain

Local Institution - 0047

🇪🇸

Madrid, Spain

Local Institution - 0125

🇸🇪

Uppsala, Sweden

Local Institution - 0076

🇨🇭

Chur, Switzerland

Local Institution - 0078

🇨🇭

Zuerich, Switzerland

Local Institution - 0157

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath